Oxitropium bromide
Chemical compound
- R03BB02 (WHO)
- (8r)-6β,7β-Epoxy-8-ethyl-3α-hydroxy-1αH,5αH-tropanium bromide (−)-tropate
- 30286-75-0
- 16735948
- SF4NW7NH7C
- ChEMBL1697846
- DTXSID0023402
- Interactive image
- [Br-].OC[C@H](c1ccccc1)C(=O)O[C@@H]2C[C@@H]3[C@H]4O[C@H]4[C@H](C2)[N+]3(C)CC
InChI
- InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13-,14-,15-,16+,17-,18+,20?;/m1./s1
- Key:LCELQERNWLBPSY-KHSTUMNDSA-M
Oxitropium bromide (trade names Oxivent, Tersigan) is an anticholinergic used as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease.[1]
It was patented in 1966 and approved for medical use in 1983.[2]
References
- v
- t
- e
Drugs for obstructive airway diseases: asthma/COPD (R03)
| Short-acting β2 agonists | |
|---|---|
| Long-acting β2 agonists |
|
| Ultra-long-acting β2 agonists | |
| Other |
muscarinic antagonist
| Leukotriene antagonists | |
|---|---|
| Arachidonate 5-lipoxygenase inhibitors | |
| Thromboxane receptor antagonists | |
| Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
